乙型肝炎后肝硬化治疗中核苷类药物的应用效果分析  

Analysis of the application effect of nucleoside drugs in the treatment of post-hepatitis B cirrhosis

作　　者：王琼[1] WANG Qiong(Hepatology Department,Tai'an Traditional Chinese Medicine Hospital,Tai'an 271001,China)

机构地区：[1]泰安市中医医院肝病科,271001

出　　处：《中国实用医药》2024年第22期112-115,共4页China Practical Medicine

基　　金：山东省中医药科技项目(项目编号:2020Q105),项目名称:基于超声E成像技术观察自拟吴茱萸补肝汤治疗阳虚型乙肝肝硬化疗效的临床研究。

摘　　要：目的 评价乙型肝炎后肝硬化治疗中核苷类药物的应用效果。方法 选择乙型肝炎后肝硬化患者78例,采用抽签法的形式分成实验组(39例,核苷类药物恩替卡韦治疗)与对照组(39例,阿德福韦酯治疗)。对比两组转阴率、不良反应发生情况及治疗前后谷丙转氨酶和病毒载量。结果 实验组转阴率89.74%高于对照组的64.10%,差异有统计学意义(P<0.05)。治疗前,两组谷丙转氨酶及病毒载量对比没有差异(P>0.05);治疗后,实验组谷丙转氨酶、病毒载量分别为(54.66±1.22)U/L、(2.33±0.56)log10拷贝/ml,均低于对照组的(71.22±2.45)U/L、(5.66±1.11)log10拷贝/ml,差异有统计学意义(P<0.05)。实验组不良反应发生率2.56%低于对照组的17.95%,差异有统计学意义(P<0.05)。结论 乙型肝炎后肝硬化治疗应用核苷类药物不仅能够提高患者的转阴率,还能降低不良反应发生率,改善各项指标,具有一定的推广价值,因此在乙型肝炎后肝硬化治疗期间需要重视核苷类药物的应用。Objective To evaluate the application effect of nucleoside drugs in the treatment of posthepatitis B cirrhosis.Methods 78 patients with post-hepatitis B cirrhosis were selected,and were divided into the experimental group(39 cases,nucleoside drug entecavir) and the control group(39 cases,adefovir) by drawing lots.The negative conversion rate,adverse reactions,alanine aminotransferase and viral load before and after treatment were compared between the two groups.Results The negative conversion rate of 89.74%in the experimental group was higher than 64.10% in the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no differences in alanine transaminase and viral load between the two groups(P>0.05).After treatment,the alanine transaminase and viral load of the experimental group were(54.66±1.22) U/L and(2.33±0.56) log10 copies/ml,which were lower than(71.22±2.45) U/L and(5.66±1.11) log10 copies/ml of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions of 2.56% in the experimental group was lower than 17.95% in the control group,and the difference was statistically significant(P<0.05).Conclusion During the treatment of post-hepatitis B cirrhosis,the application of nucleoside drugs can not only improve the negative conversion rate of patients,but also reduce the incidence of adverse reactions and improve various indicators,which has a certain promotion value.Attention should be paid to the application of nucleoside drugs during the treatment of post-hepatitis cirrhosis.

关 键 词：乙型肝炎 肝硬化 核苷类药物 转阴率 

分 类 号：R512.62[医药卫生—内科学] R575.2[医药卫生—临床医学]